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22 Breast cancer chemotherapy, although very potent against tumour tissue, results in significant 
23 cardiovascular toxicity. The focus of research in this area has been predominantly towards 
24 cardiotoxicity. There is limited evidence detailing the impact of such treatment on the 
25 vasculature despite its central importance within the cardiovascular system and resultant 
26 detrimental effects of damage and dysfunction. This review highlights the impact of 
27 chemotherapy for breast cancer on the vascular endothelium. We consider the most likely 
28 mechanisms of endothelial toxicity to be through direct damage and dysfunction of the 
29 endothelium. There are sharp consequences of these detrimental effects as they can lead to 
30 cardiovascular disease. However, there is potential for exercise to alleviate some of the 
31 vascular toxicity of chemotherapy, and the evidence for this is provided. The potential role of 
32 exercise in protecting against vascular toxicity is explained, highlighting the recent in-human 
33 and animal model exercise interventions. Lastly, the mediating mechanisms of exercise 
34 protection of endothelial health is discussed, focusing on the importance of exercise for 
35 endothelial health, function, repair, inflammation and hyperlipidaemia, angiogenesis, and 
36 vascular remodelling. These are all important counteracting measures against chemotherapy-
37 induced toxicity and are discussed in detail. 
38
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45 Breast cancer is the most common form of cancer, with over 2 million women diagnosed 
46 globally in 2018 [1]. The breast cancer 10-year survival rate increased over the past 40 
47 years from 40% to 78% due to early detection and effective treatments [1].. There are 
48 different types of breast cancer, which vary according to site; and as with all cancer types, 
49 there are different stages of breast cancer, according to progression, which influences the 
50 chosen treatment regimens [2]. For early-stage breast cancer, lumpectomy followed by 
51 radiation therapy, or simple mastectomy are the major treatment decisions. Additionally, 
52 adjuvant chemotherapy and 5-10 years of endocrine therapy are often recommended, with 
53 anti-herceptin2 agents, including trastuzumab, prescribed in addition for those with node-
54 negative, hormone receptor–positive breast cancer [2]. This review will focus specifically on 
55 the common chemotherapy regimens prescribed in early-stage breast cancer. This often 
56 consists of a combination of drugs including anthracyclines, anti-metabolites, alkylating 
57 agents, and    taxanes [3].  These drugs work together in different ways to eradicate cancerous 
58 tumours. Anthracycline drugs, including doxorubicin and its analogue, epirubicin, inhibit 
59 topoisomerase, preventing mitosis and induces cellular damage via generation of oxidative 
60 stress by production of reactive oxygen species (ROS) [3]. Antimetabolite drugs, such as 5-
61 fluorouracil (5-FU), damage RNA, DNA and inhibit DNA synthesis [3]. Alkylating agents, 
62 such as cyclophosphamide, alkylate nucleophilic bases in tumour DNA, forming crosslinks 
63 between and within DNA strands, creating breakages and preventing DNA replication [3]. 
64 Lastly, taxanes (e.g. paclitaxel and docetaxel) interfere with cell division through disruption 
65 of microtubule function [3]. Together, these mechanisms cause activation of tumour cell 
66 apoptosis, making them effective in reducing neoplastic growth [3].
67 The systemic nature of intravenous chemotherapy means that the toxic effects of the drugs 
68 are not only carried out in the tumour cell, but also of cells within the cardiovascular system 
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69 (CVS). Cardiovascular toxicity is associated with clinically relevant detrimental effects, with 
70 cardiovascular disease (CVD) being the leading cause of mortality in breast cancer survivors, 
71 attributed to 15.9% of deaths, followed closely by breast cancer (15.1%) [4], highlighting that 
72 cardiovascular detriments may be more damaging than the cancer itself. Risk of CVD 
73 mortality is 1.9-fold higher in breast cancer survivors than in the general population [5]. 
74 Research into cardiovascular toxicity of chemotherapy is essential to increase the likelihood 
75 of disease-free survival and to improve quality of life in breast cancer survivors, and there is 
76 a growing body of evidence regarding the pathophysiology of the condition. However, the 
77 focus of research has been predominantly on the cardiac consequences of chemotherapy 
78 toxicity. The impact these drugs have on the vasculature have often been overlooked, despite 
79 its central and mediating role in the CVS. However, there is now emerging evidence for the 
80 importance of the vasculature in CVD development with chemotherapy exposure.   
81 The vascular endothelium is the first point of contact with any intravenous chemotherapy 
82 treatment and is adversely affected by this exposure, presenting as endothelial dysfunction [3, 
83 6] and increased cell death [7]. The endothelium is responsible for the production of the 
84 potent vasodilator, nitric oxide (NO), which plays a key role in regulating normotension, and 
85 has an important role in maintaining cardiovascular health via anti-thrombotic and anti-
86 platelet properties [8]. Endothelial damage may in fact be one of the mediating mechanisms 
87 behind the initial cardiotoxicity which leads to chronic cardiovascular conditions and, 
88 ultimately premature death in cancer sufferers [6]. Hence, it is important to understand the 
89 role of the endothelium to provide a mechanistic basis for the initiation and progression of 
90 CVD with chemotherapy exposure. This will help to elucidate if there are potential 
91 interventions or treatments which can prevent, reverse, or attenuate the cardiotoxicity of 
92 cancer treatment. 
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93 Since cardiotoxicity is a poignant clinical issue for breast cancer survivors and their 
94 clinicians, there is a requirement for interventions which reduce toxicity. Exercise has been 
95 proposed as an effective low-cost, low-risk, and low-burden adjunct treatment for those 
96 undergoing chemotherapy. For example, exercise interventions during adjuvant breast cancer 
97 treatment have resulted in lower risk for cardiovascular events [9], greater blood pressure 
98 reduction [10], improved vascular function [11, 12], prevention of atherosclerosis [12], de-
99 stiffening of arteries [13–15], and increased skeletal muscle angiogenesis [16]. As with 
100 research into the toxicity itself, research into exercise interventions have also focused mainly 
101 on cardiac benefits, despite the importance of the vasculature for prevention of progression to 
102 CVD [6]. Therefore, this review will focus on the vascular endothelial involvement in 
103 potential exercise protection against cardiovascular toxicity, highlighting current knowledge, 
104 potential pathways of protective mechanisms, and the requirement for further research in this 
105 field.
106 Cardiotoxicity of Chemotherapy: Clinical Cardiac Manifestations
107 Acute Toxicity of Chemotherapy
108 Chemotherapy drugs have different associated cardiovascular toxicologies depending on the 
109 chosen regimen. Some of these effects can be observed immediately, whereas some 
110 cardiovascular detriments develop more slowly. Anti-metabolites such as 5-FU have 
111 immediate effects, with 1-68% of patients receiving develop cardiotoxicity during 
112 chemotherapy cycles, resulting in 2-13% of the affected patients dying during the treatment 
113 course [17]. Cyclophosphamide also effects the CVS immediately during treatment with a 
114 5% incidence of cardiac complications [18]. Cyclophosphamide has also been associated with 
115 development of heart failure with reduced LVEF, which often manifests 1-10 days after the 
116 first cycle, with a prevalence of 7-28%, depending on dose [17]. Taxane exposure associates 
117 with 5% incidence of cardiac complications, occurring around 7 months post-treatment [19], 
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118 including a 2-8% incidence of heart failure, with significantly reduced LVEF and 1.7% 
119 incidence of ischaemia [17]
120 Chronic Toxicity of Chemotherapy
121 In breast cancer patients, it is reported that the overall incidence of heart failure is 5% in 
122 patients treated with anthracyclines [20]. The incidence of cardiotoxicity from anthracyclines 
123 varies depending on dosage and which drug is used, with doxorubicin eliciting incidence of 
124 toxicity of 3-26% and epirubicin eliciting a 1-3% incidence [3]. Anthracycline-induced 
125 cardiotoxicity often manifests as significantly reduced LVEF [15]. This cardiotoxicity occurs 
126 during treatment and may never recover fully, with only 11% of patients having full recovery 
127 of LVEF, and 71% of patients having partial recovery (LVEF remaining <50%) 5-years post-
128 treatment [20].
129 Protective Effects of Exercise on the Cardiovascular System in Cancer Survivors. 
130 To prevent cardiotoxicity, clinicians consider reducing the treatment dose and using cardiac 
131 monitoring to detect the early phase of cardiotoxicity [17]. However, dose attenuation may 
132 interfere with efficacy of treatment. Therefore, there is scope for other adjunct therapies to 
133 attenuate cardiotoxicity. So far, pharmaceutical interventions have been used, including 
134 neurohormonal blockers and antihypertensives [17] but these increase treatment costs and 
135 have their own side effects. There is hope for exercise as an adjunct treatment to attenuate 
136 cardiovascular toxicity as this is both effective, cost-efficient, and has almost no detrimental 
137 effects on cancer patients [9–12, 16]. 
138 The American Heart Association have proposed development of a model to detect those at 
139 risk of cardiotoxicity with chemotherapy and to implement a comprehensive cardiac 
140 rehabilitation programme within cancer care to tackle the ever-growing problem [21]. This 
141 proposal has strong justification as there is evidence emerging for the protective effects of 
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142 exercise on the CVS in cancer survivors [9–12, 16]. In cancer patients who had completed 
143 treatment, Framingham risk scores post-exercise intervention were 2% in the exercise group 
144 and 13% in the usual care group, associating with an 11% decrease in the predicted 10-year 
145 risk of developing CVD [9]. Additionally, more leisure time physical activity was associated 
146 with reduced CVD risk in an 8-year follow-up study of breast cancer women treated with 
147 chemotherapy [22]. Moreover, aerobic fitness has an inverse association with chemotherapy-
148 induced cardiac fibrosis incidence [23], and higher baseline physical activity is associated 
149 with an attenuation in the usual decline in LVEF [24]. Aerobic fitness can be enhanced with 
150 exercise training, and therefore, adds to the evidence that exercise could potentially reduce 
151 cardiotoxicity of chemotherapy. However, it is important to note that these studies present 
152 associations only and highlight a need for randomized controlled trials of exercise.
153 As with the studies investigating the cardiotoxicity of chemotherapy, exercise and physical 
154 activity studies have focused mainly on cardiac outcomes. However, beneficial effects of 
155 exercise during chemotherapy have also been observed for vascular health and function [9-
156 12]. The importance of the vasculature’s role in treatment toxicity and the potential for 
157 exercise to attenuate this, as well as mechanistic links, will be reviewed in subsequent 
158 sections.
159 Vascular Dysfunction as a Predictor for Cardiotoxicity
160 Vascular endothelial damage and dysfunction may have a role in early detection and 
161 development of chemotherapy toxicity. Flow mediated dilation (FMD) is a non-invasive 
162 measurement of NO-mediated endothelium-dependent dilation, assessing the vasodilatory 
163 response to a sudden return of blood flow after a period of venous occlusion [8]. An increase 
164 in blood flow increases shear stress across the endothelium, stimulating release of NO (potent 
165 vasodilator), inducing vasodilation [8]. The relative change in artery diameter is predictive of 
166 the endothelium’s capacity to release NO [8]. A 2.7% decrease in FMD associates with a 
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167 37% increased likelihood for LVEF reduction at 3 months post-chemotherapy in breast 
168 cancer patients [25]. Furthermore, arterial stiffness has recently been described as key 
169 measure for CVD risk profiling in patients treated with similar anti-cancer drugs [26]. Pulse 
170 wave velocity (PWV) is a non-invasive bioassay for arterial stiffness and is an important 
171 predictor of cardiovascular disease and mortality in breast cancer patients [27]. PWV is 
172 determined by the velocity at which the blood pressure pulse propagates through the 
173 circulatory system by measuring the time for a pulse wave to travel from the carotid to the 
174 femoral arteries, relative to the distance travelled. A 27%  increase in pulse wave velocity 
175 after the third cycle of chemotherapy independently predicts LVEF decrease after 
176 chemotherapy completion [28]. Vascular remodelling also predicts cardiotoxicity, with a 4% 
177 increase in arterial stiffness associating with a 7% reduction in LVEF [29].  This indicates 
178 that changes within the vasculature occur alongside changes in cardiac function and hence, 
179 could be used as screening tools to predict cardiotoxicity risk at an early stage. This is 
180 important as toxicity may be reversed at an early stage but irreversible when LVEF is 
181 affected [15]. Early detection and intervention are superior methods of care over managing 
182 late-stage CVD and heart failure. However, measurements of vascular health, including 
183 FMD, PWV, and arterial stiffness, are not incorporated into routine clinical care, despite 
184 potential to detect early cardiotoxicity to allow effective intervention. 
185
186 Vascular Damage/Dysfunction with Chemotherapy & Potential Exercise Protection
187 There is substantial cellular harm within the vasculature (Figure 1) which may contribute to 
188 the detrimental impact of chemotherapy on the whole CVS. The endothelium is the first 
189 organ in contact with intravenous chemotherapy and is damaged by this exposure [3, 6, 7, 
190 30]. Chemotherapy-induced endothelial damage may play a significant role in aiding the 
191 development of cardiotoxicity, and there is evidence implicating vascular injury and 
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192 dysfunction as an initiating step for CVD onset and progression [6, 31]. Therefore, this gives 
193 an opportunity to assess vascular health as a detector of early cardiotoxicity, allowing for 
194 early intervention or treatment attenuation. As with cardiac detriments, exercise may alleviate 
195 vascular toxicity of chemotherapy. Exercise has well-documented benefits, including lower 
196 risk for overall cardiovascular events [9], reduced blood pressure [10], improved endothelial 
197 function [11, 12], prevention of atherosclerotic development [12], de-stiffening of arteries 
198 [13–15], and increased angiogenesis [16]. The potential vascular-mediated mechanisms for 
199 exercise protection will be outlined with respect to attenuating chemotherapy-induced 
200 cardiovascular toxicity. 
201 The detrimental effects of chemotherapy on the endothelium manifest as vascular dysfunction 
202 and may contribute to myocardial ischaemia which is particularly prevalent in those treated 
203 with 5-FU with an incidence >20% [32]. The most common symptom of this cardiotoxicity is 
204 angina due to myocardial ischaemia, as shown by ST-segment changes [32]. This ischemia 
205 often occurs without obstruction of the coronary arteries but with increased vasoconstriction, 
206 indicative of vasospasm due to vascular endothelial dysfunction – and likely detrimental 
207 impacts on the vascular smooth muscle are also implicated – reducing oxygen supply to 
208 cardiac tissue [31, 32]. Myocardial ischaemia also occurs with cyclophosphamide [33] and 
209 taxane [3] exposure. Although less common (<5%) than observed with 5-FU, coronary 
210 vasospasm is also the proposed mechanism of cardiotoxicity for cyclophosphamide [33]. Due 
211 to this proposed underlying mechanism, cyclophosphamide, taxane, and 5-FU toxicity 
212 research should focus on vascular pathophysiology to elucidate potential strategies to 
213 attenuate myocardial ischaemia to increase the chances of disease-free survival. 
214
215 The Role of Endothelial Damage in Toxicity and the Potential for Attenuation by 
216 Exercise 
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217 Hypertension is a side effect of chemotherapy treatment, particularly well-documented in 
218 cyclophosphamide [3, 31], with this drug attributing to 43% of severe pulmonary 
219 hypertension in animal models [3]. Cyclophosphamide-induced hypertension associates with 
220 acute endothelial damage, consequently disrupting the signalling pathway essential for 
221 control of NO-mediated vasodilation and blood pressure regulation [31]. Endothelial damage 
222 may also lead to the enlarged myocardium which is seen with patients treated with 
223 cyclophosphamide chemotherapy [34]. Direct endothelial damage from exposure to 
224 cyclophosphamide results in leakage of plasma proteins and erythrocytes, causing wall 
225 thickening due to interstitial oedema and haemorrhage which may reduce left ventricular 
226 diastolic function and presents as cardiomyopathy [34]. Damage to the endothelium in the 
227 coronary vasculature results in leakage of toxic metabolites which directly damage 
228 cardiomyocytes [33]. This may create an access route for other chemotherapy drugs into the 
229 heart, contributing to cardiotoxicity. The mechanism behind anthracycline- and docetaxel-
230 mediated endothelial injury has been linked to increased intracellular levels of oxidative 
231 stress, leading to the activation of apoptotic signalling pathways [3, 29]. This occurs within 
232 the endothelium, leading to further vascular damage and dysfunction. Oxidative stress also 
233 causes increased permeability of the endothelium by exerting a detrimental effect on 
234 endothelial junction proteins [35], with anthracyclines increasing permeability of arterial 
235 endothelial cells by ∼10-fold, resulting in large decreases in ATP and antioxidants from the 
236 endothelium [36], further inducing metabolic dysfunction, oxidative stress, and apoptosis. 
237 Overall, chemotherapy treatment increases the susceptibility to vascular damage and 
238 dysfunction, with cellular apoptosis within the CVS outlined as the main mehcanism for 
239 cardiotoxicity [31]. Mechanisms of action include damaging RNA and DNA; inhibition of 
240 topoisomerase; increasing oxidative stress; and binding and stabilizing tubulin [3]. These 
241 mechanisms ultimately lead to inhibition of cell division and initiation of cellular apoptosis 
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242 [3]. Since these actions are non-specific, they induce apoptosis throughout the whole CVS. 
243 The potential mechanisms by which chemotherapy induces cellular apoptosis are outlined in 
244 Figure 1. Vascular manifestations of this damage has a consequential ripple effect on each 
245 other and on overall cardiovascular health, and there is now evidence suggesting that vascular 
246 injury and dysfunction is an initiating step in CVD development [31]. For example, coronary 
247 artery disease usually occurs due to an accumulation of atherosclerotic plaques, mediated by 
248 vascular damage and inflammation [37]. Narrowing of the vessels results in hypertension, 
249 increasing cardiac stress due to pressure overload [37]. Restricted coronary arteries lead to 
250 reduction of blood supply to the myocardium, and depending of the severity of blood flow 
251 reduction, may result in MI. MI may occur with chemotherapy exposure [33] due to the 
252 increased risk of atherosclerosis, myocardial ischaemia, and hypertension, increasing the risk 
253 of the embolism breaking away from the localised site [33]. The sudden deprivation of blood 
254 supply with an MI causes apoptosis and necrosis of the myocardium and alteration of cardiac 
255 electrical stimulation. If the patient survives an acute MI, the myocardium attempts to recover 
256 via growth of cardiomyocytes. This results in pathological remodelling and hypertrophy, 
257 accompanied by fibrous tissue development [38], creating mechanical stiffness and cardiac 
258 dysfunction, leading to heart failure and an endless cycle of cardiovascular detriments. The 
259 mechanisms by which chemotherapy-induced cardiomyocyte and vascular damage may lead 
260 to heart failure are illustrated in Figure 2. 
261 Exercise training has been found to reduce apoptosis in cardiomyocytes exposed to 
262 doxorubicin [39], most likely due to enhanced levels of antioxidants and reduced levels of 
263 reactive oxygen species [40]. Therefore, a potential mechanism for exercise protection 
264 against endothelial toxicity is through attenuation of oxidative stress and apoptosis. Reduced 
265 oxidative stress and subsequent reductions in apoptosis may protect against CVD risk, as 
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266 oxidative stress and endothelial apoptosis are contributing factors to chemotherapy toxicity 
267 [2, 28, 30]. 
268 The Role of Endothelial Function (eNOS) in Toxicity and the Potential for Attenuation 
269 with Exercise 
270 One of the most critical effects of chemotherapy is likely to be the detrimental effects of these 
271 drugs on the key vasodilator and antithrombotic enzyme, endothelial nitric oxide synthase 
272 (eNOS). Chemotherapy drugs have been found to reduce eNOS bioavailability and/or 
273 activation within the endothelium [3, 6, 30, 41], likely attributed to oxidative stress [41]. 
274 Overall, detriments in the endothelial vasodilatory pathway are likely responsible for the 
275 subsequent vasospasm and vasoconstriction, as seen with chemotherapy [6, 30]. As NO is 
276 anti-thrombotic, impairment in its production is also likely to be involved in the increased 
277 incidence of venous thromboembolism in patients treated with chemotherapy [42]. 
278 Interestingly, cyclophosphamide has been associated with increased microcirculatory 
279 relaxation and eNOS content, but this is likely to be a compensatory mechanism for the high 
280 levels of endothelial injury induced by cyclophosphamide exposure [7].  Disruption of NO 
281 regulation is also seen within anthracycline chemotherapy, as assessed by FMD [12]. There is 
282 a 7% reduction in FMD from pre- to post-anthracycline treatment [12] due to anthracycline-
283 induced endothelial damage [3]. This indicates that there is a reduction in NO bioavailability 
284 which increases the risk for CVD [25]. Reduced endothelial-dependent vasodilation is 
285 clinically significant as FMD inversely associates with LVEF reduction in BC patients treated 
286 with chemotherapy [25] and may be a mediating mechanism behind the 5% incidence of 
287 heart failure observed with anthracycline treatment [20].
288 An exercise intervention during chemotherapy increased FMD by 4% in breast cancer 
289 patients, suggesting enhanced endothelial function and eNOS production [12]. This is 
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290 promising for reducing risk of cardiovascular events as eNOS has anti-atherogenic properties, 
291 reducing the risk of atherosclerosis development. These results are echoed in non-
292 chemotherapy studies of exercise training, and FMD improvements have been found to be 
293 mediated by shear stress [43]. With 12 weeks of thrice weekly cycling during treatment (60-
294 100% VO2Peak, 30-45 minutes), a  non-significant increase in FMD was observed from pre-to 
295 post-doxorubicin-cyclophosphamide chemotherapy in the exercise group, with no change in 
296 usual care controls [11]. More promising results were found with an 8-week thrice weekly 
297 high-intensity interval training (HIIT) cycling intervention alongside anthracycline 
298 chemotherapy, whereby post-intervention, brachial FMD increased by 4% with exercise 
299 compared to the 7% reduction in FMD in the usual care group [12]. This is a clinically 
300 meaningful finding, as a 2.7% increase in FMD associates with a 37% decreased likelihood 
301 for LVEF reduction at 3 months post-chemotherapy in BC patients 
302 Although there are now some, although few, in-human studies of exercise training before and 
303 during chemotherapy for breast cancer, some preliminary evidence from murine models 
304 should be highlighted.  Eight, but not four weeks of exercise training (5 days/week, 30 
305 minutes running 20-25m/min) prior to exposure to chemotherapy was associated with 
306 enhanced endothelium-dependent vasodilation in rats [44], suggesting that exercise-induced 
307 protective effects on the vasculature is dose-dependent. Exercise training (6 weeks, 5 
308 days/week, 30 minutes running at 50-60% maximum velocity) during doxorubicin treatment 
309 was associated with reduction in mortality, alongside an improved endothelium-independent 
310 but not endothelium-dependent vasodilation, in rats with doxorubicin-induced cardiac 
311 dysfunction [45]. This suggests that exercise restores vascular function, but the mechanism 
312 may not be via increased NO bioavailability but rather via improved vascular structure and/or 
313 vascular smooth muscle properties. The discrepancies in mechanistic findings between 
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314 Matsuura et al. (2010) and Hayward et al. (2004) highlight a requirement for further 
315 investigation.
316 The Role of Vasoconstrictors in Toxicity and the Potential for Exercise Modulation
317 Another mediating mechanism behind exercise-induced protection of vascular toxicity is 
318 likely to be the downregulation of vasoconstrictive factors, such as the potent vasoconstrictor, 
319 endothelin-1. Chemotherapy treatment increases activity of endothelin-1 leading to a 
320 phenotype in favour of vasoconstriction and hypertension and is likely a postulating 
321 mechanism of 5-FU-induced vasospasm [3]. In addition, endothelin-1 inhibits eNOS activity 
322 and is a likely mediator of the downregulation of eNOS observed in 5-FU [6]. 
323 Vasoconstriction is also upregulated with exposure to anthracyclines [6] but endothelin-1 
324 expression has not been investigated with anthracycline exposure. Nevertheless, the increase 
325 in vasoconstriction leads to hypertension which poses a risk to cardiovascular health as an 
326 increased pressure in the vessels increases the likelihood of plaque rupture and vascular 
327 events, alongside an increased pre-load and strain on the myocardium, worsening any cardiac 
328 dysfunction, consequently leading to heart failure if left untreated (Figure 1). In contrast to 
329 other chemotherapy drugs, taxanes have been found to reduce endothelin-1 expression in 
330 breast cancer patients, which may improve overall survival [46]. On the contrary, exercise 
331 studies in non-cancer older women have shown that exercise is associated with reduction in 
332 vasoconstrictive factors occurring alongside improved blood pressure profiles [47]. An 
333 exercise intervention in healthy older women decreased plasma endothelin-1 concentration 
334 from 2.9 ± 0.2 pg/ml to 2.2 ± 0.2 pg/ml, occurring alongside a reduction in systolic (127±4 
335 mmHg to 112±3 mmHg) and diastolic (79±2 mmHg to 65±2 mmHg) blood pressure [47]. 
336 Overall, exercise appears to promote a pro-vasodilatory phenotype which subsequently 
337 reduces hypertension risk and improves overall cardiovascular health. 
338 Exercise has the Potential to Attenuate Chemotherapy-Induced Arterial Stiffness
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339 Arterial stiffness is another key component of vascular dysfunction with anti-cancer therapies 
340 [26]. Chemotherapy treatment results in remodelling of the resistance vessels whereby the 
341 structure of the vessels changed towards a larger lumen, suggesting significant endothelial 
342 injury, as this is a compensatory mechanism to decrease blood pressure [7]. However, 
343 remodelling leads to stiffened blood vessels with reduced compliance related to increased 
344 oxidative stress with taxane treatment [29] and decreased NO-dependent vasodilation with 
345 doxorubicin exposure [48]. Arterial stiffness with chemotherapy also occurs due to structural 
346 remodelling initiated by elastin degradation and advanced glycation end products formation, 
347 mediated by TNF-α-dependent vascular inflammation [49]. Changes in vascular compliance 
348 associate with reductions in cardiac function due to a consequently hypertensive state 
349 increasing cardiac afterload and cardiac stress, inducing significant cardiac detriments, with 
350 LVEF reducing by 7% from pre- to post-treatment [29].  This indicates that reductions in 
351 cardiac function occur alongside changes in vascular structure. 
352 Interestingly, exercise has the potential to reduce arterial stiffness, with those participating in 
353 lifelong exercise have lower arterial stiffness relative to age-matched sedentary counterparts 
354 [14, 15].  Exercise during and after chemotherapy is associated with reduced circulating 
355 inflammatory cytokines IL-6, IL-10, IL-1β and TNF-α [50], which has the potential to 
356 attenuate TNF-α-induced arterial stiffness [49]. In vivo animal models have provided 
357 mechanistic links for this exercise effect, with improved PWV in mice after voluntary wheel 
358 running attributed to reduced oxidative stress, mechanical stiffness and accumulation of 
359 collagen-I and advanced glycation end products [13]. This may well be the case with exercise 
360 during chemotherapy but as yet, no study has undertaken this investigation. Nevertheless, this 
361 may be a contributory effect for reduction of cardiotoxicity with exercise training during 
362 chemotherapy, as this reduces the likelihood of hypertension and subsequent organ damage, 
363 reducing treatment toxicity [51].
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364 Exercise Reduces Thrombosis Risk
365 The incidence of venous thromboembolism in patients treated with FEC was 17%, which is 
366 higher than any other chemotherapy regime (1.5-10%) [42]. The reason for this particularly 
367 high incidence is not well understood and current suggestions for the effects may be due to 
368 participant characteristics and high treatment dosage [42]. It must be considered that the 
369 increased incidence of hypertension with cyclophosphamide will be a contributing factor to 
370 thromboembolism as increased pressure can cause plaque rupture. Cyclophosphamide and 5-
371 FU alone also associate with thrombosis [3], leading to myocardial infarction (MI) [26] and 
372 stroke [31]. The mechanisms of action associated with these drugs pose a high risk to the 
373 health and integrity of the vasculature due to endothelial cell damage [3], increasing 
374 susceptibility to pro-thrombotic phenotypes. The issue of thrombotic risk needs to be 
375 addressed to improve quality of life and survival in those undergoing chemotherapy 
376 regimens.
377 Exercise may help to reverse the dysfunctional shift towards a pro-thrombotic endothelial cell 
378 morphology induced by chemotherapy. An 8-week exercise intervention during the course of 
379 chemotherapy prevented the usual increase in carotid intima media thickness with 
380 chemotherapy treatment, suggesting a protective effect of exercise against atherosclerotic risk 
381 [12]. Basally, the endothelium has low adhesion molecule expression which is upregulated by 
382 stimuli such as inflammation and disturbed blood flow.  Endothelial activation presents as 
383 increased adhesion molecule expression which is important for thrombotic risk [52]. 
384 E‐selectin, vascular cell adhesion molecule-1 (VCAM-1), and intracellular adhesion 
385 molecule-1 (ICAM-1) are involved in the rolling and adhesion of leukocytes to the activated 
386 endothelium, initiating the development of atherosclerosis [52]. The expression of ICAM-1 is 
387 of particular importance as this associates with overall and disease-free survival [52]. ICAM-
388 1 is upregulated with taxane exposure [52] and anthracycline exposure [53] and is the likely 
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389 mechanism of action for vascular toxicity of cyclophosphamide [3]. As eNOS downregulates 
390 endothelial adhesion molecule expression, the increased expression of adhesion molecules is 
391 likely a consequence of the reduced expression of eNOS which occurs with chemotherapy 
392 exposure [54], increasing the likelihood of atherosclerosis development. However, there is 
393 not yet enough evidence for this effect in chemotherapy drugs and therefore, requires further 
394 research for confirmation. Exercise, through increasing eNOS expression and activation, may 
395 reduce adhesion molecule expression which is an important mediator of vascular risk. There 
396 has been no study to-date which has investigated this in cancer patients but is likely to be a 
397 mediating mechanism as exercise in non-cancer clinical populations has been found to reduce 
398 circulating plasma levels of endothelial-derived adhesion molecule expression, specifically E-
399 selectin and ICAM-1 [55]. One of the potential reasons for the downregulation of adhesion 
400 molecules on endothelial cells is thought to be shear stress. Exercise results in an increase in 
401 laminar blood flow across the vascular endothelium, and in vitro studies have shown that 
402 increasing shear stress results in reduced expression of VCAM-1 and E-selectin, but 
403 interestingly an increase in ICAM-1 [56]. This suggests another mechanism responsible for 
404 exercise-induced downregulation of ICAM-1 and requires further investigation. 
405 Another potential mechanism for exercise protection against thrombotic risk is the ability to 
406 regulate inflammation and cholesterol flux [50]. With chemotherapy-induced vascular 
407 toxicity, the anti-inflammatory properties of the endothelium are diminished [31] and 
408 chemotherapy has also been found to increase triglycerides, total cholesterol, and low-density 
409 lipoprotein, which are associated with elevated CVD risk [57]. This, together with the 
410 downregulation of eNOS [3, 6, 30] and upregulation of adhesion molecules [52, 53], is likely 
411 to lead to the onset and/or progression of atherosclerosis with the accumulation of 
412 inflammatory and lipid molecules within the vasculature. Exercise during and after 
413 chemotherapy is associated with a reduction in inflammatory cytokines IL-6, IL-10, IL-1β 
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414 and TNF-α [50] and improved lipid profiles with increased high-density lipoprotein and 
415 reduced total cholesterol [9]. This may be a contributory effect for reduction of cardiotoxicity 
416 with exercise training during chemotherapy, as this reduces the likelihood of atherosclerotic 
417 development, posing a counteraction against anti-neoplastic treatment toxicity.
418 Exercise Promotes Skeletal Muscle Angiogenesis
419 As well as macrovascular health, muscle angiogenesis also improves with exercise during 
420 chemotherapy treatment [16]. Skeletal muscle biopsies show that capillary density was 
421 reduced by 10% with chemotherapy [16]. This reduced skeletal muscle perfusion may 
422 contribute to muscle atrophy and dysfunction commonly observed in cancer patients 
423 undergoing chemotherapy. However, 16-weeks of twice weekly HIIT cycling plus 20 
424 minutes continuous cycling or plus resistance exercise training, alongside chemotherapy 
425 increased capillary density by 30%, attenuating this vascular toxicity [16]. With 
426 cyclophosphamide and docetaxel exposure, circulating levels of the pro-angiogenic signalling 
427 factor, VEGF are reduced which is directly associated with hypertension and stroke risk [3, 
428 31]. VEGF is required for efficient angiogenesis as it signals the formation of new blood 
429 vessels in hypoxic regions and facilitates repair of damaged vessels – a key process to protect 
430 against vascular disease. Disruption of the VEGF pathway with docetaxel has been associated 
431 with the reduction in eNOS activation [3]. Therefore, VEGF is not only important for 
432 angiogenesis but is essential for NO production, subsequent vasodilation and anti-thrombotic 
433 properties which are protective to the vasculature. Targeting VEGF has shown to be a 
434 therapeutic strategy for preventing doxorubicin-mediated endothelial dysfunction [58], 
435 potentially through modulation of doxorubicin-induced vascular mitochondrial ROS 
436 upregulation [59]. Even although exercise-induced increases in circulating VEGF could 
437 possibly prevent chemotherapy-induced cardiotoxicity, there has been no observable effect of 
438 exercise during chemotherapy on levels of circulating VEGF [11]. However, this has only 
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439 been investigated in one study and requires further investigation for confirmation. Despite the 
440 minimal evidence against VEGF upregulation with exercise during chemotherapy, 
441 angiogenesis has been shown to increase by 30% in skeletal muscle, compared to a 10% 
442 decrease in non-exercise controls, helping to combat chemotherapy-induced muscular 
443 atrophy and dysfunction [16]. Therefore, skeletal muscle angiogenesis may well improve 
444 with exercise training during chemotherapy. Whether this is mediated by exercise-induced 
445 alterations in VEGF should be explored further. It may be a concern that the pro-angiogenic 
446 effect of exercise may reduce treatment efficacy as some treatments work through reduction 
447 of tumour angiogenesis but, in the same study, exercise also associated with decreased 
448 tumour blood flow [16]. It can be argued that reducing tumour blood flow is preferrable as 
449 this starves the tumour of its oxygen and nutrient supply, thereby killing the tumour. 
450 However, in some cases, such as in mice, exercise during chemotherapy increased tumour 
451 microvessel density, vessel maturity and perfusion, and reduced intra-tumoral hypoxia, 
452 associating with significantly reduced tumour growth and increased tumour apoptosis [60]. 
453 Therefore, improving angiogenesis within tumours may actually increase efficacy of 
454 chemotherapy as this is improving the supply route for the drugs to reach the tumour [61]. 
455 Importantly, exercise induces a normalization of tumour vasculature due to shear stress 
456 induced angiogenesis, as compared with angiogenesis as a hallmark of cancer which 
457 produces ‘leaky’ and disorganised pathological vessels which reduce treatment efficacy and 
458 increase the chance of metastasis [61]. Therefore, exercise may protect from vascular toxicity 
459 by increasing capillary number, which in turn can be beneficial for efficacy of the 
460 chemotherapy treatment itself. 
461 Exercise Promotes Vascular Regenerative Capacity
462 To expand our understanding of exercise-induced endothelial protection, evidence for the 
463 implications of chemotherapy on endothelial repair must also be outlined. Endothelial repair 
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464 is an important function of the endothelium to protect against dysfunction and plaque 
465 formation as endothelial damage without repair is often the initiating step for progression to 
466 pathological vascular states [5, 30]. A wound healing assay showed impaired ability of 
467 endothelial cells to migrate across the site of injury when exposed to 5-FU and epirubicin [6]; 
468 and epirubicin and 5-FU have also been found to decrease migration, as shown by Boyden’s 
469 chamber assay, likely due to cell cycle arrest and downregulation of NO which is involved in 
470 the migration signalling pathway [6]. Endothelial progenitor cells (EPCs) are implicated in 
471 reparative processes to maintain the integrity of the endothelial layer [62]. There is limited 
472 evidence for the effect of chemotherapy on EPCs and therefore is a potential area for future 
473 research. However, docetaxel has been shown to reduce levels of circulating EPCs, likely due 
474 to increased apoptosis and inflammatory mediators [63]. This is associated with CVD and 
475 mortality, highlighting the problem of anti-neoplastic drugs on the CVS [63]. This, together 
476 with the previously mentioned disruption of the VEGF signalling pathway with docetaxel [3], 
477 leads to an endothelium with reduced capacity for repair of vascular damage, increasing the 
478 risk for development of CVD. Positively, exercise in breast cancer patients has been found to 
479 increase circulating EPCs and angiogenic factors [11]. More evidence for the potential 
480 benefits of effects on EPCs comes from non-cancer studies, with acute execise found to 
481 mobilise EPCs and regular exercise found to increase resting EPC numbers in both healthy 
482 and heart failure populations, likely contributing to exercise-induced improvements in 
483 endothelial function [62]. Hence, exercise may protect from vascular toxicity by increasing 
484 repair, possibly through upregulation of EPCs and pro-angiogenic factors; and fortunately, 
485 improved vascular networks do not appear to affect treatment efficacy.
486 A summary of exercise interventions in humans and animal models can be found in Table 1. 
487 Additionally, overall mechanisms by which exercise may attenuate vascular damage and 
488 dysfunction from chemotherapy are outlined in Figure 3. 
Page 20 of 34
vb@bioscientifica.com
Manuscript submitted for review to Vascular Biology
For Review Only
21
489 Exercise Mimetics 
490 Interestingly, exercise mimetics have been proposed as therapeutics to prevent CVD in those 
491 ‘at risk’ from the disease. The concept of exercise mimetics is that a polypill containing 
492 several compounds which lower blood lipids, reduce blood pressure, are anti-thrombotic, 
493 blunt autonomic responses, and lower blood glucose concentration, may protect against CVD, 
494 in a similar way to exercise [64]. In human studies have shown that the short-term use of a 
495 polypill (amlodipine 2.5 mg, losartan 25 mg, hydrochlorothiazide 12.5 mg and simvastatin 40 
496 mg) can reduce CVD risk by ~80% [64]. This may be an alternative therapeutic strategy for 
497 preventing/treating vascular dysfunction with chemotherapy drugs, given the barriers to 
498 exercise in cancer populations [65]. This said, exercise interventions have been successfully 
499 implemented in cancer patients undergoing chemotherapy [8-12] and hence, may be a more 
500 wide-reaching and low-cost therapeutic strategy.
501 Research Gaps – A Call for Action 
502 There are several research gaps which should be outlined with regards to both cardiovascular 
503 toxicity and potential exercise protection. Until recently, research has focused on 
504 cardiotoxicity of chemotherapy but now research is considering vascular consequences of 
505 cancer treatment. Despite initial evidence, there is still a paucity of research into the 
506 vasculature, with only a small number of in-human studies which focus on vascular 
507 endothelial health upon chemotherapy exposure. More research is required to confirm and 
508 expand on current knowledge regarding the endothelium’s role in initiation and development 
509 of chemotherapy-induced CVD and the mechanisms involved. Despite the proposed 
510 mechanisms in this review having a high likelihood for involvement in cardiotoxicity of 
511 chemotherapy they have not yet been fully elucidated in cancer care. Therefore, further 
512 investigations to confirm the underlying mechanisms of vascular toxicity are needed. In 
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513 addition to this, most evidence for cardiotoxicity comes from studies investigating 
514 doxorubicin and there are very few studies investigating chemotherapy for breast cancer, 
515 despite also causing cardiotoxicity and their use being common in patient care [3]. 
516 More research gaps are evident when scrutinising the literature that has investigated exercise 
517 protection against toxicity. There are only a small number of studies investigating vascular 
518 outcomes with exercise interventions during chemotherapy, and there are even fewer studies 
519 proposing underlying mechanisms for this. Furthermore, most exercise studies have 
520 investigated anthracyclines despite the multiplicity of chemotherapy drugs utilised in breast 
521 cancer care. A full review of  the mechanisms by which exercise may improve vascular 
522 function in the specific setting of anthracycline chemotherapy are discussed in depth 
523 elsewhere [66]. Despite gaps in the literature, these studies show promise for the potential 
524 inclusion of exercise therapy during cancer treatment. Future randomized controlled trials of 
525 exercise in those undergoing chemotherapy should assess vascular health and function 
526 outcomes including blood pressure, FMD, circulating endothelial cells, EPCs and pulse wave 
527 velocity to fully determine the vascular benefits of exercise in this population. As yet, the 
528 majority of evidence for exercise protective mechanisms comes from non-chemotherapy 
529 treated populations and hence, assumptions regarding interdisciplinary consistency have been 
530 drawn. Despite the likelihood that these studies are still applicable to cancer treatment, there 
531 is a strong requirement for conformational studies regarding the mechanisms of exercise 
532 protection against vascular damage and dysfunction with chemotherapy. 
533 Conclusion
534 Chemotherapy exposure is associated with cardiovascular toxicity, which is linked to CVD 
535 development and mortality, and is the number one cause of death in breast cancer patients 
536 [4]. This is highly likely to be due to, in part, the toxic effects of chemotherapy drugs on the 
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537 vasculature. The underlying pathology involves vascular dysfunction which results in 
538 ischaemia, hypertension, and thrombosis which can lead to cardiovascular events including 
539 arrythmias, heart failure, and MI. This is likely due to increased activation and apoptosis of 
540 vascular cells inducing a significant shift in the endothelial health from an anti-thrombotic, 
541 anti-coagulative, vasodilatory phenotype to a phenotype which promotes vasoconstriction, 
542 atherosclerosis, and thrombosis. Focusing on attenuation of vascular endothelial damage 
543 could provide a much-needed alleviation of cardiotoxicity. Exercise shows promise as an 
544 adjunct therapy to reduce vascular toxicity, by improving or maintaining endothelial function, 
545 reducing inflammation and hyperlipidaemia, as well as promoting endothelial repair. The 
546 emerging evidence outlined provides promise for exercise as a potential therapeutic but there 
547 are still several research gaps. Future research should include studies elucidating potential 
548 mechanisms behind endothelial protection of exercise in this patient population; and large 
549 exercise trials in breast cancer patients are required to ensure exercise effects are applicable 
550 and feasible for breast cancer survivors.
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763 Table 1. Summary of exercise interventions in rodents and humans investigating vascular 




768 Figure 1. Mechanisms of chemotherapy-induced apoptosis via activation of caspase cascade. 
769 Reactive oxygen species (ROS), adenosine triphosphate (ATP).
770
771 Figure 2. Potential mechanisms by which chemotherapy induces cardiac dysfunction via 
772 endothelial and cardiomyocyte damage. 
773
774 Figure 3. Mechanisms of chemotherapy toxicity on the endothelium and counteractive 
775 effects of exercise. Vascular endothelial growth factor (VEGF), endothelial nitric oxide 
776 synthase (eNOS), vascular smooth muscle cell (VSMC), endothelial progenitor cells (EPCs), 
777 low density lipoprotein cholesterol (LDL-C).
778
779
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Treatment






rats n=40 per 
group
Intervention group: Treadmill 5 
days/week for 4 or 8 weeks, 30 min/day, 
20-25 m/min, 15% gradient 
Sedentary group: No exercise 
Ex vivo exposure 
to 5-fluorouracil 






eNOS protein content 
No diff Intervention Vs Sedentary Group 
at 4 weeks
 EDV Intervention Group Only at 8 
weeks
No diff Intervention Vs Sedentary Group 
at 4 weeks 
 eNOS Content Intervention Group 
Only at 8 weeks
[35] Betof et 
al., 2015
Sprague Dawley 
rats n=10 per 
group
Intervention group: Treadmill 5 
days/week, for 6 weeks, 30 min/day, 50-
60% max velocity 









eNOS content and 
activity 
Impaired in both groups 
No diff Intervention Vs Sedentary Group 
No diff Intervention Vs Sedentary Group 
[36] Scott et 
al., 2014
BALB/c female 
mice n=11 per 
group 
Intervention group: voluntary wheel 
running for 18 days





days 7, 9, and 11)
Microvessel density 
 
 Microvessel Density Intervention vs 
Sedentary Group
Participants Exercise Intervention Chemotherapy 
Treatment
Vascular Outcomes Overall Findings
Human 
Studies




age 51± 6 years, 
BMI 29±5kg/m2, 
n= 10 per group
Intervention:12 weeks, 3 sessions/week 
cycling at 60-100% O2peak for 30-45min 𝑉
Control: usual care only






every 3 weeks 
baFMD No diff Pre- to Post-Chemotherapy 
Treatment
No diff Intervention Vs Sedentary Group
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[12] Lee et 
al., 2019
stage I-III breast 




Intervention: 8 weeks, 3 sessions/week 
20-min cycling HIIT (7x1-min at 90% 
PPO)





every 2 weeks for 




cIMT pre to post 
treatment 
 baFMD Pre- to Post-Chemotherapy 
Treatment Sedentary Group
 baFMD Pre- to Post-Chemotherapy 
Treatment Intervention Group
 cIMT Pre- to Post-Chemotherapy 
Treatment Sedentary Group
No change cIMT Pre- to Post-






age 51±13 years, 
BMI 25kg/m2 
(n=23)
Resistance training: 12 weeks, 2 
sessions/week 2-3 sets of 8–12 reps 70-
80% 1-RM, 3x3-min of HIIT cycling 
(n=6)
Aerobic training: 12 weeks, 2 
sessions/week, 20 min cycling/running 
RPE 13–15, 3x3-min of HIIT cycling 
(n=7)
Control: usual care only (n=10)
Anthracyclines, 
taxanes, or a 
combination of 
the two (dosage 
details not 
provided)
Capillaries per fibre 
pre to post treatment:
 
 capillaries Pre- to Post-Chemotherapy 
Treatment Sedentary Group
 capillaries Pre- to Post-Chemotherapy 
Treatment Aerobic Intervention Group 
 capillaries Pre- to Post-Chemotherapy 
Treatment Resistance Intervention Group
Brachial flow mediated dilation (baFMD), peak power output (PPO), carotid intima media thickness (cIMT), Rating of Perceived Exertion 
(RPE), Endothelium-Dependent Vasodilation (EDV)
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Figure 1. Mechanisms of chemotherapy-induced apoptosis via activation of caspase cascade. Reactive 
oxygen species (ROS), adenosine triphosphate (ATP). 
338x190mm (96 x 96 DPI) 
Page 32 of 34
vb@bioscientifica.com
Manuscript submitted for review to Vascular Biology
For Review Only
 
Figure 2. Potential mechanisms by which chemotherapy induces cardiac dysfunction via endothelial and 
cardiomyocyte damage. 
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Figure 3. Mechanisms of chemotherapy toxicity on the endothelium and counteractive effects of exercise. 
Vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), vascular smooth muscle 
cell (VSMC), endothelial progenitor cells (EPCs), low density lipoprotein cholesterol (LDL-C). 
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